{
    "clinical_study": {
        "@rank": "45054", 
        "arm_group": [
            {
                "arm_group_label": "Brimonidine Tartrate 0.025%", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the intraocular Pressure (IOP) lowering response\n      and evaluate the safety of brimonidine tartrate 0.025% ophthalmic solution in adult subjects\n      with open angle glaucoma or ocular hypertension."
        }, 
        "brief_title": "Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Glaucoma and Ocular Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be at least 18 years of age at Visit 1 (Screening), of either sex and any race\n\n          -  Be willing and able to provide written informed consent prior to any study procedures\n             being performed.\n\n          -  Be willing and able to follow all instructions and attend all study visits.\n\n          -  Be willing to discontinue use of disallowed medication\n\n          -  Have a documented diagnosis of ocular hypertension, open angle glaucoma or chronic\n             angle closure glaucoma with a patent iridotomy.\n\n        Exclusion Criteria:\n\n          -  Have known sensitivity or poor tolerance to brimonidine or any other component of the\n             study medications.\n\n          -  Have any form of glaucoma other than open-angle glaucoma, ocular hypertension or\n             chronic angle closure glaucoma with patent iridotomy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687426", 
            "org_study_id": "12-150-0001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Brimonidine Tartrate 0.025%", 
                    "Vehicle"
                ], 
                "description": "1 drop in each eye daily four times a day for 14 days", 
                "intervention_name": "Brimonidine Tartrate 0.025%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Brimonidine Tartrate 0.025%", 
                    "Vehicle"
                ], 
                "description": "1 drop in each eye daily four times a day for 14 days", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 21, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Winchester", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01890"
                }, 
                "name": "Clinical Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension", 
        "other_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety", 
            "safety_issue": "Yes", 
            "time_frame": "For up to 8 weeks"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "IOP", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687426"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eye Therapies, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eye Therapies, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}